title: [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2006)].
abstract: From October 2006 to September 2007, we collected the specimen from 356 patients with lower respiratory tract infections in 14 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 414 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, 407 strains were examined. The isolated bacteria were: Staphylococcus aureus 64, Streptococcus pneumoniae 96, Haemophilus influenzae 87, Pseudomonas aeruginosa (non-mucoid) 52, P. aeruginosa (mucoid) 11, Klebsiella pneumoniae 20, and Moraxella catarrhalis 44. Of 64 S. aureus strains, those with 2 microg/ml or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 microg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 27 (42.2%) and 37 (57.8%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all strains at 0.063 microg/ml or less. Against MRSA, vancomycin and linezolid showed the most potent activity and inhibited the growth of all the strains at 1 microg/ml. Carbapenems showed the most potent activities against S. pneumoniae and in particular, panipenem inhibited the growth of all the strains at 0.063 microg/ml or less. Imipenem and faropenem also had a preferable activity and inhibited the growth of all the strains at 0.125 and 0.5 microg/ml, respectively. In contrast, there were high-resistant strains (MIC: over 128 microg/ml) for erythromycin (45.8%) and clindamycin (20.8%). Against H. influenzae, levofloxacin showed the most potent activity and its MIC90 was 0.063 microg/ml or less. Meropenem showed the most potent activity against P. aeruginosa (mucoid) and its MIC90 was 0.5 microg/ml. Against P. aeruginosa (non-mucoid), tobramycin had the most potent activity and its MIC90 was 2 microg/ml. Against K. pneumoniae, cefozopran was the most potent activity and inhibited the growth of all the strains at 0.063 microg/ml or less. Also, all the antibacterial agents except ampicillin generally showed a potent activity against M. catarrhalis and the MIC90 of them were 2 microg/ml or less. The approximately half the number (50.6%) of the patients with respiratory infection were aged 70 years or older. Bacterial pneumonia and chronic bronchitis accounted for 49.2% and 28.1% of all the respiratory infections, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (29.2%), S. aureus (20.8%), and H. influenzae (12.9%). H. influenzae (25.0%) and P. aeruginosa (21.7%) also were frequently isolated from the patients with chronic bronchitis. Before the antibacterial agent administration, the bacteria frequently isolated from the patients were S. pneumoniae (27.5%) and H. influenzae (22.5%). The bacteria frequently isolated from the patients treated with macrolides was P. aeruginosa, and its isolation frequently was 39.4%.
authors.forename: Hajime
authors.initials: H
authors.lastname: Goto
authors.forename: Hideki
authors.initials: H
authors.lastname: Takeda
authors.forename: Shin
authors.initials: S
authors.lastname: Kawai
authors.forename: Akira
authors.initials: A
authors.lastname: Suwabe
authors.forename: Suguru
authors.initials: S
authors.lastname: Watanabe
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Okazaki
authors.forename: Yugo
authors.initials: Y
authors.lastname: Ashino
authors.forename: Kaoru
authors.initials: K
authors.lastname: Shimada
authors.forename: Nobuki
authors.initials: N
authors.lastname: Aoki
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Sato
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Honma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Mori
authors.forename: Kouichiro
authors.initials: K
authors.lastname: Kudo
authors.forename: Haruhito
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Shigemi
authors.initials: S
authors.lastname: Kondo
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Tanaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Kido
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Toyoko
authors.initials: T
authors.lastname: Oguri
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Nakamori
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inoue
authors.forename: Kohei
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Midori
authors.initials: M
authors.lastname: Sumitomo
authors.forename: Shigeatsu
authors.initials: S
authors.lastname: Endo
authors.forename: Toshihide
authors.initials: T
authors.lastname: Nakadate
authors.forename: Mikio
authors.initials: M
authors.lastname: Oka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kobashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Saita
authors.forename: Katsunori
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Akira
authors.initials: A
authors.lastname: Kondou
authors.forename: Junichi
authors.initials: J
authors.lastname: Matsuda
authors.forename: Michiko
authors.initials: M
authors.lastname: Nakano
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Satoru
authors.initials: S
authors.lastname: Oikawa
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000382:microbiology*